Ratings GNI Group Ltd.

Equities

2160

JP3386370005

Market Closed - Japan Exchange Other stock markets 11:30:00 10/05/2024 am IST			5-day change	1st Jan Change
2,417 ^JPY	+0.96%		-0.98%	-14.59%

19/03	Jefferies Adjusts GNI Group’s Price Target to 4,100 Yen From 3,000 Yen, Keeps at Buy	MT
14/02	GNI Group Ltd. Provides Consolidated Earnings Guidance for the Full Year Ending December 2024	CI

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The group's activity appears highly profitable thanks to its outperforming net margins.
Over the last twelve months, the sales forecast has been frequently revised upwards.
Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
For several months, analysts have been revising their EPS estimates roughly upwards.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Over the past four months, analysts' average price target has been revised upwards significantly.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
GNI GROUP LTD.	-14.59%	767M	-
MODERNA, INC.	+17.61%	47.02B	B-
LONZA GROUP AG	+48.77%	41.86B	A
IQVIA HOLDINGS INC.	+1.05%	41.76B	B
CELLTRION, INC.	-4.27%	28.8B	C
ICON PUBLIC LIMITED COMPANY	+12.01%	26.05B	B-
ALNYLAM PHARMACEUTICALS, INC.	-21.47%	19.15B	B
BIO-TECHNE CORPORATION	+4.35%	12.55B	B+
MEDPACE HOLDINGS, INC.	+28.27%	12.34B	C+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-4.32%	11.82B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes